RT Journal Article
SR Electronic
T1 Sex-Specific Associations of the Plasma-Proteome with incident Coronary Artery Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.02.17.24302702
DO 10.1101/2024.02.17.24302702
A1 Sier, Vincent Q.
A1 van Dijk, Ko Willems
A1 van Heemst, Diana
A1 Quax, Paul H.A.
A1 Jukema, J. Wouter
A1 Noordam, Raymond
A1 de Vries, Margreet R.
YR 2024
UL http://medrxiv.org/content/early/2024/02/18/2024.02.17.24302702.abstract
AB Background and Aims The aetiology of coronary artery disease (CAD) is different for men and women, yet insights into underlying sex-specific biological and pathophysiological mechanisms are limited. We investigated the sex-specific associations of the plasma-proteome with incident CAD.Methods In 40,829 participants from UK Biobank free-of-CAD from baseline to 365 days thereafter (55% women, mean 56.9±8.1 years), we analysed associations between 2,922 plasma-proteins and CAD incidence. Baseline plasma samples (2006-2010), were analysed in relation to incident CAD over a median follow-up of 13.7 (IQR: 13.1,14.4) years. Combined and sex-specific analyses were performed using Cox-proportional hazard models, adjusting for considered confounders, and causal inference using Mendelian Randomisation (MR).Results Multivariable-adjusted Cox-proportional hazard models identified 1,138 proteins associated with incident CAD (false-discovery-rate-corrected p-value<0.05), of which 219 showed evidence for potential causality using MR. Overrepresentation analyses identified involvement of cytokine-cytokine receptor interactions (p<0.0001), matrix remodelling (p<0.0001), regulation of innate and adaptive immune cells (p<0.0001), and angiogenesis (p<0.0001) pathways associated with incident CAD. Sex-specific analyses revealed additional 412 female-exclusive and 37 male-exclusive proteins and distinct CAD-risk pathways were identified for women (e.g., innate immune response) and men (e.g., tube morphogenesis (angiogenesis)). Translation toward druggability on targets with causal evidence revealed sex-specific clinical drug candidates such as C1S (men) and FOXO1 (women).Conclusions Although the majority of proteins showed consistent associations with incident CAD in both sexes, multiple proteins and biological pathways were either more strongly associated with incident CAD in men or in women, potentially indicating sex-specific pathogenesis and opening new alleys for prevention and clinical strategies.Visual abstractCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a Leiden University Medical Centre MD/PhD research grant to V.Q. Sier.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used ONLY open available human data that were available in their original form at (https://www.ukbiobank.ac.uk/). Summary data are available from the original sources. Summary-level data used for the two-sample Mendelian Randomisation analyses are available online through the infrastructure of the R package twosampleMR or on the website of the FinnGen Biobank (https://www.finngen.fi/en)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes